Asston Pharmaceu

When is the next results date for Asston Pharmaceu?

Asston Pharmaceu is scheduled to announce its results on 14 November 2025.

Asston Pharmaceu is scheduled to declare its results on 14 November 2025.

How has been the historical performance of Asston Pharmaceu?

Asston Pharmaceu experienced significant growth from March 2024 to March 2025, with net sales rising to 25.04 Cr from 15.59 Cr, and profit after tax increasing to 4.33 Cr from 1.36 Cr. Key metrics such as EPS improved to 6.91 and operating profit margin rose to 24.64%, indicating a strengthening financial position.

Answer:<BR>The historical performance of Asston Pharmaceu shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Asston Pharmaceu reported net sales of 25.04 Cr in March 2025, a notable increase from 15.59 Cr in March 2024. Total operating income also rose to 25.04 Cr from 15.59 Cr, driven by an increase in raw material costs to 14.13 Cr from 9.75 Cr. The total expenditure, excluding depreciation, increased to 18.87 Cr from 13.04 Cr, resulting in an operating profit (PBDIT) of 6.74 Cr, up from 2.80 Cr. Profit before tax surged to 5.70 Cr from 1.82 Cr, leading to a profit after tax of 4.33 Cr, compared to 1.36 Cr the previous year. The earnings per share (EPS) improved significantly to 6.91 from 2.18, while the operating profit margin increased to 24.64% from 16.36%. The total assets of the company grew to 28.10 Cr from 20.70 Cr, with total liabilities also rising to 28.10 Cr from 20.70 Cr. The book value per share adjusted increased to 17.6 from 11.45, reflecting the company's strengthening financial position.

Is Asston Pharmaceu overvalued or undervalued?

As of November 26, 2025, Asston Pharmaceu is considered overvalued with a PE ratio of 22.11, a price-to-book value of 2.20, and an EV to EBITDA ratio of 16.35, despite outperforming the Sensex with a 1-week return of 17.65%.

As of 26 November 2025, Asston Pharmaceu's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued, with a price-to-earnings (PE) ratio of 22.11, a price-to-book value of 2.20, and an EV to EBITDA ratio of 16.35. These metrics suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Asston Pharmaceu's PE ratio is lower than that of Sun Pharma (37.53) and Divi's Lab (69.71), both categorized as expensive, while it is slightly higher than Cipla (22.59) and Dr. Reddy's Labs (18.02), which are viewed as attractive. The company's recent stock performance has outpaced the Sensex, with a 1-week return of 17.65% compared to the Sensex's 0.50%, reinforcing the notion of overvaluation in the current market context.

Which are the latest news on Asston Pharmaceu?

Why is Asston Pharmaceuticals Ltd falling/rising?

As of 11-Apr, the stock price of Asston Pharmaceuticals Ltd is at 87.29, showing an 11.91% increase over the past week, outperforming the Sensex. However, declining investor participation and erratic trading behavior may raise concerns about the stock's stability.

As of 11-Apr, the stock price of Asston Pharmaceuticals Ltd is currently at 87.29, with no change from the previous trading session. The stock has shown a significant upward trend over the past week, rising by 11.91%, which is notably higher than the Sensex's increase of 5.77% during the same period. Additionally, over the past month, the stock has increased by 6.45%, while the Sensex has decreased by 0.84%. Year-to-date, Asston Pharmaceuticals Ltd has outperformed the Sensex with a gain of 5.77% compared to the Sensex's decline of 9.00%.<BR><BR>Today's trading performance indicates that the stock has outperformed its sector by 14.18%. It opened with a substantial gain of 14.84% and reached an intraday high of Rs 87.29. However, it is important to note that the stock has not traded on 2 out of the last 20 days, indicating erratic trading behavior. Furthermore, there has been a significant drop in investor participation, with delivery volume on 06 April falling by 67.39% compared to the 5-day average.<BR><BR>Despite the positive price movements and outperformance against the sector, the declining investor participation and erratic trading may raise concerns about the stock's stability. Overall, the current rise in Asston Pharmaceuticals Ltd's stock price can be attributed to its strong performance relative to the market and sector, despite some underlying issues with trading consistency and investor engagement.